Previous 10 | Next 10 |
2023-09-18 16:38:46 ET More on PTC Therapeutics Seeking Alpha’s Quant Rating on PTC Therapeutics Historical earnings data for PTC Therapeutics Financial information for PTC Therapeutics PTC Therapeutics: Struggling Still But Potential Remains P...
2023-09-15 13:11:06 ET Gainers: MSP Recovery ( LIFW ) +199% . AERWINS Technologies ( AWIN ) +104% . AgriFORCE Growing Systems Ltd. ( AGRI ) +40% . RayzeBio ( RYZB ) +37% . Novonix Limited ( NVX ) +31% . Greenland Technologies...
2023-09-15 10:00:12 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...
CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization PR Newswire - Conference call to be held at 8: 45 am EDT - SOUTH PLAINFIELD, N.J. , Sept. 15, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced t...
BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of...
PTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community PR Newswire - 2023 recipients include patient advocacy organizations in Australia and Brazil - SOUTH PLAINFIELD, N.J. , Sept. 7, 2023 /PRNewsw...
PTC Therapeutics to Present Recent Data for Sepiapterin at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium PR Newswire - Results from the APHENITY trial in PKU and long-term extension study including Phe tolerance to be highlighted - ...
2023-08-25 13:38:37 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rare disease stocks have a difficult task. The rarer a disease is, the less public research goes into studying it. And that in turn makes it more difficult for a company to develop and test eff...
2023-08-21 08:10:52 ET Summary PTC Therapeutics, Inc. lacks solid margins and revenue streams, increasing investment risks. The company focuses on developing medicines for rare disorders, but a failed drug test caused stock price to tumble. The company's profitability is low, ...
2023-08-04 00:05:23 ET PTC Therapeutics, Inc. (PTCT) Q2 2023 Earnings Conference Call August 03, 2023 04:30 PM ET Company Participants Ron Aldridge - Senior Director, Investor Relations Matthew Klein - Chief Executive Officer Eric Pauwels - Chief Business Officer...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....
CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review PR Newswire - PTC to submit a request for re-examination - WARREN, N.J. , June 28, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announce...
Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients PR Newswire - FDA lifts PTC518 partial clinical hold based on PIVOT-HD data - - Conference call and webcast to be held ...